Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company that uses biomarkers and augmented intelligence to help physicians identify the source of chronic low back pain, announced the appointment of Daniel Keefe as Commercial Director, Western U.S. Keefe will lead commercial efforts across the Western region, building on Aclarion’s existing footprint and supporting continued adoption of Nociscan.
Keefe brings more than 20 years of experience in medical device and healthcare technology sales, including leadership roles at Centinel Spine, Brainlab, Zimmer Biomet, and Intuitive Surgical. Most recently, he served as Regional Sales Manager at Centinel Spine, where he consistently exceeded performance targets and delivered significant year-over-year growth across Northern California. His appointment reflects Aclarion’s focus on expanding momentum and deepening adoption in a key strategic region.
“Dan brings a proven track record of driving commercial growth and expanding adoption of innovative surgical technologies. His deep experience working with spine surgeons and hospital systems, combined with his ability to build and scale high-performing territories, will be instrumental as we continue to grow our presence in the Western U.S. and support broader clinical use of Nociscan,” said Brent Ness, Chief Executive Officer of Aclarion.
Nociscan is the first evidence-supported, cloud-based platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. It objectively quantifies chemical biomarkers associated with disc pain, and when used with other diagnostic tools, provides critical insights into the location of low back pain. The technology demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated.
An estimated 266 million people worldwide live with chronic low back pain. Aclarion’s Nociscan solution addresses this pervasive health challenge. The expansion of the commercial team comes amid triple-digit growth in utilization of Nociscan, with engagement spanning academic institutions and high-volume private practice spine centers across the Western U.S.
“I’m excited to join Aclarion at a time when Nociscan is gaining meaningful traction across the clinical community. The ability to provide physicians with objective insight into the source of pain represents a significant advancement in how chronic low back pain is evaluated. I look forward to working with physicians and spine centers across the Western U.S. to expand access to Nociscan and support its continued integration into clinical practice,” said Daniel Keefe.
For more information, visit www.aclarion.com. To find a Nociscan center, view the site map here.
